Pharma Equity aktie (PEG) | Pressmeddelande

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cance...

GlobeNewswire • 23 Oct 10:28

Major shareholder announcement - Pharma Equity Group A/S

GlobeNewswire • 14 Oct 08:17

Managers’ transactions

GlobeNewswire • 14 Oct 08:00

Pharma Equity Group announces successful completion of directed issue of new shares

GlobeNewswire • 11 Oct 08:37

Pharma Equity Group announces issuance of new shares in a direct issue

GlobeNewswire • 04 Oct 13:52

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rig...

GlobeNewswire • 04 Oct 09:01

Consolidated Interim Report 1 January – 30 June 2024

GlobeNewswire • 16 Aug 08:52

The Board of Directors' decision to issue convertible loans

GlobeNewswire • 16 Jul 10:09

Major shareholder announcement - Pharma Equity Group A/S

GlobeNewswire • 15 Jul 16:23

Major shareholder announcement - Pharma Equity Group A/S

GlobeNewswire • 15 Jul 16:13

Results of extraordinary general meeting in Pharma Equity Group A/S

GlobeNewswire • 03 Jun 16:17

The Board of Director's decision to issue convertible loans

GlobeNewswire • 16 May 12:35

Consolidated interim report 1 January – 31 March 2024

GlobeNewswire • 16 May 07:27

Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S

GlobeNewswire • 08 May 15:17

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

GlobeNewswire • 08 May 10:20

Major shareholder announcement - Pharma Equity Group A/S

GlobeNewswire • 23 Apr 11:45

Passing of the General Meeting of Pharma Equity Group A/S

GlobeNewswire • 16 Apr 17:29

The Board of Director's decision to issue convertible loans

GlobeNewswire • 10 Apr 14:21

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the ...

GlobeNewswire • 05 Apr 11:22

Notice convening the annual general meeting in Pharma Equity Group A/S

GlobeNewswire • 25 Mar 13:06

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK00611...

GlobeNewswire • 22 Mar 09:00

Completion of subscription of convertible loans

GlobeNewswire • 21 Mar 16:33

Correction: Pharma Equity Group A/S - Annual Report 2023

GlobeNewswire • 20 Mar 17:15

Pharma Equity Group A/S - Annual Report 2023

GlobeNewswire • 20 Mar 08:58

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the...

GlobeNewswire • 05 Mar 10:11

Completion of subscription of convertible loans

GlobeNewswire • 07 Feb 13:38

The Board of Director's decision to issue convertible loans

GlobeNewswire • 07 Feb 09:46

Completion of subscription of convertible loans

GlobeNewswire • 25 Jan 10:08

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate ba...

GlobeNewswire • 22 Jan 16:15

The Board of Director's decision to issue convertible loans

GlobeNewswire • 22 Jan 15:54

Status of the Company's receivable from Portinho S.A.

Status of the Company's receivable from Portinho S.

GlobeNewswire • 28 Nov 2023 18:30

2024 Financial Calendar

GlobeNewswire • 28 Nov 2023 14:56

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candida...

GlobeNewswire • 16 Nov 2023 12:17

Consolidated interim report 1 January – 30 September 2023

GlobeNewswire • 16 Nov 2023 08:26

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S

GlobeNewswire • 02 Nov 2023 15:14

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for p...

GlobeNewswire • 31 Oct 2023 13:18

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its top...

GlobeNewswire • 31 Oct 2023 11:57

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

GlobeNewswire • 11 Oct 2023 12:27

Status of the Company's receivables from Portinho S.A.

Status of the Company's receivables from Portinho S.

GlobeNewswire • 25 Sep 2023 20:49

Consolidated interim report 1 January – 30 June 2023

GlobeNewswire • 16 Aug 2023 08:19

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical wound-healing composition.

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent o...

GlobeNewswire • 15 Aug 2023 13:54

Status of the company's receivables from Portinho S.A. with payment deadline 1 July 2023

Status of the company's receivables from Portinho S.

GlobeNewswire • 30 Jun 2023 17:56

Changes to the Board of Directors in Pharma Equity Group

GlobeNewswire • 15 Jun 2023 12:00

New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals A/S

GlobeNewswire • 14 Jun 2023 08:30

Encouraging preliminary data from the first part of a clinical study in pouchitis

GlobeNewswire • 08 Jun 2023 17:00

HC Andersen Capital: Pharma Equity Group – Lifescience investment company with twofold strategy

Cision • 05 Jun 2023 09:10

Settlement - Purchase of shares

GlobeNewswire • 02 Jun 2023 11:52

Managers’ transactions

GlobeNewswire • 25 May 2023 10:31

Consolidated interim report 1 January – 31 March 2023

GlobeNewswire • 10 May 2023 06:49

Forløb af ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 10. februar 2023

Forløb af ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 10.

GlobeNewswire • 10 Feb 2023 14:15

Börskollen

För dig med koll på börsen

Pressmeddelanden från Pharma Equity

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Major shareholder announcement - Pharma Equity Group A/S

Managers’ transactions

Pharma Equity Group announces successful completion of directed issue of new shares

Pharma Equity Group announces issuance of new shares in a direct issue

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Consolidated Interim Report 1 January – 30 June 2024

The Board of Directors' decision to issue convertible loans

Major shareholder announcement - Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S

Results of extraordinary general meeting in Pharma Equity Group A/S

The Board of Director's decision to issue convertible loans

Consolidated interim report 1 January – 31 March 2024

Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S

The Board of Director's decision to issue convertible loans

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Completion of subscription of convertible loans

Correction: Pharma Equity Group A/S - Annual Report 2023

Pharma Equity Group A/S - Annual Report 2023

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Completion of subscription of convertible loans

The Board of Director's decision to issue convertible loans

Completion of subscription of convertible loans

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

The Board of Director's decision to issue convertible loans

Status of the Company's receivable from Portinho S.A.

2024 Financial Calendar

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.

Consolidated interim report 1 January – 30 September 2023

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

Status of the Company's receivables from Portinho S.A.

Consolidated interim report 1 January – 30 June 2023

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical wound-healing composition.

Status of the company's receivables from Portinho S.A. with payment deadline 1 July 2023

Changes to the Board of Directors in Pharma Equity Group

New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals A/S

Encouraging preliminary data from the first part of a clinical study in pouchitis

HC Andersen Capital: Pharma Equity Group – Lifescience investment company with twofold strategy

Settlement - Purchase of shares

Managers’ transactions

Consolidated interim report 1 January – 31 March 2023

Forløb af ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 10. februar 2023